News of Note—Heat-stable TB shot, measles outbreak and more


Here is some other vaccine news of note for the week:

> Scientists have started phase 1 testing of ID93, a freeze-dried, temperature-stable recombinant tuberculosis vaccine candidate developed at the Infectious Disease Research Institute. NIH release

> The number of confirmed cases of measles in western Washington has grown to 36, as health officials have declared a state of emergency and are urging immunization. NPR article


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> A new poll by South Nassau Communities Hospital showed that parents are aware of the HPV vaccine but that some have no plans—or are unsure—whether they’ll have their children immunized. Newsday article

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.